STUDY DESIGN AND METHODS:
MStroC and mesenchymal stem cell (MSC) proliferative capacities were studied in bulk cultures and single-cell cultures with assay of secondary replating capacity of individual clones. Flow-cytometric phenotype analysis and proliferative history analysis were also performed.
RESULTS:
In cultures initiated with previously amplified and cryopreserved MStroC from human marrow, Xuri medium enabled a total cell expansion fold comparable to one obtained in control fetal calf serum (FCS)-supplemented culture. However, both the number and the proliferative capacity of colony-forming unit-fibroblast were greatly reduced in Xuri medium cultures. This is even more evident in single-cell cultures, where, in rare positive wells, only several cells were found in Xuri cultures, compared to abundant cell content in FCS and a-minimal essential medium cultures. Replating these single-cell clones in secondary cultures (FCS in both cases) revealed a total exhaustion of MSC proliferative capacity after Xuri primary culture.
CONCLUSION:
Since in both conditions after a 7-day bulk culture, similar immunophenotype and proliferative history were found when the standard MSC immunophenotype panel was employed, the loss of proliferative capacity in Xuri medium shows that it cannot maintain functional MSC population. This is a drastic example showing that the real MSC activity can be completely unrelated to the immunophenotype considered as MSC phenotype.
M esenchymal stromal cells (MStroC) represent adherent fibroblastoid cell population originating from marrow, fat tissue, Wharton jelly, and so forth. In spite of relatively high level of morphologic homogeneity, this MStroC population is heterogeneous from the functional viewpoint. Usually, less than one-half of MStroC comprises the cells exhibiting capacity of colony formation (colonyforming unit-fibroblast [CFU-F]). The CFU-F entity was, in fact, initially identified as mesenchymal stem cell (MSC;  1,2 discussed in Ivanovich and Vlaski   3 ). Inside this CFU-F population, only a fraction of cells (18%-34%) is multipotent, that is, corresponds to bona fide definition of MSCs, while the others are either bipotent or unipotent progenitors. 4 At least one-half of MStroC population is composed of postprogenitor fibroblastoid cells exhibiting a low proliferative capacity, hence not exhibiting the colony-forming ability. 5 Over the past decade, the functionally heterogeneous MStroC population 6 (mainly inadequately termed "mesenchymal stem cells") is largely considered in cell therapy in terms of either tissue regeneration or immunomodulation. 7 The general tendency in development of clinical scale procedure is to create the 
MATERIALS AND METHODS
Human marrow MStroC were obtained and cryopreserved as described previously. 9 The cells previously produced in the standard aMEM cultures supplemented with the FCS and basic fibroblast growth factor (bFGF) and cryopreserved after three to five passages were thawed and plated in flasks of 25 or 75 cm 2 in 5 or 10 mL of medium, respectively, and cell concentrations 25,000 or 32,000/mL, respectively. For the control condition (1), the standard aMEM (Lonza) supplemented with 10% of FCS (VF Hyclone SV30160.03, Fisher Scientific), 2 mmol/L ultra-glutamine II (Lonza), 100 ng/L penicillin, 100 ng/L streptomycin antibiotics (penicillin G potassium/streptomycin sulfate S-9137, Sigma Aldrich), and 1 ng/mL bFGF (Peprotech). Test culture (2) was performed with medium Xuri (GE-Healthcare), supplemented with 0.6% of growth solution commercialized together with the medium. For this condition, the flasks were coated overnight with Xuri MSC attachment solution (from the same kit), which was diluted 100 times in phosphate-buffered saline (PBS) and used in volume of 5 and 10 mL for the flasks of 25 and 75 cm 2 , respectively. For the 96-well plates, 100 mL was used. The flasks and the plates were kept at 48C until use for the cultures when the solution was removed and the flasks and plates washed with PBS. A combined condition (3), Xuri supplemented with 0.6% of growth solution and 2.5% of FCS was also tested. The cells were cultured for 7 days at 378C and 5% of CO 2 . Before plating the cells in culture, as well as after 7 days (end of the culture) a sample was taken for CFU-F determination.
CFU-F determination
A total of 250 to 600 MStroC were seeded either in 30-or in 90-mm-diameter dishes in aMEM supplemented as described (3 or 5 mL, respectively). After 14 days of culture, the macroscopic colonies were stained with May Gr€ unwald Giemsa and counted. Alternatively, the colonies were observed in the native state under the microscope and photographed.
Single MStroC culture
To determine the influence of culture conditions on individual MStroC proliferative capacity, the cells were, after thawing, seeded in 96-well plates in a concentration of one cell/well by using a cell sorter (BDfax Aria, Becton Dickinson). In this case, only two conditions were studied: aMEM supplemented as explained above (control condition) and Xuri medium with growth solution; for Xuri condition the wells were coated as explained.
Replating of the clones originating from the single MStroC
After 7 days of single MStroC culture, the wells were observed under inverted microscope to determine the presence or absence of a clone in well. After the cells were detached by trypsin (or by using Accutase) the whole cell content of a clone (from positive wells) was replated in a new well (48-well plates containing 500 mL of fully supplemented aMEM) for both conditions of single-cell culture. The cultures were incubated for 14 days at 378C and 5% CO 2 . The degree of confluence in 48-well plates was observed by inverted microscope after 4, 8, and 14 days of culture. The cultures were stopped at Day 14 and adherent cells colored in situ by May Gr€ unwald Giemsa.
Immunophenotypic characterization of MStroC
After the bulk cultures, in Xuri medium or in aMEM, the cells were stained either by CD90 and CD73 only or by a panel of monoclonal antibodies directed to CD105, CD90, CD73, CD45, CD34, CD14, CD11b, CD79a (or CD19), and 
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HLA-DR. For this purpose, various combinations of immunofluorescent antibodies were used (Table 1) .
According to the standard quality control (QC) definition 10 MSCs should be positive for CD105, CD90, and CD73 and negative for other markers mentioned. The cells were analyzed by flow cytometry on Day 7, after being previously labeled for 20 minutes at 48C in dark by 1 mL of antibody per 100,000 cells in PBS supplemented with 2 mmol/L EDTA and 0.8% bovine serum albumin.
Proliferative history of MStroC in culture
To track the proliferative history of the cells in culture, MStroC were stained by DiD (Vybrant DiD cell labeling solution, Life Technologies) as explained previously.
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The cells were briefly incubated for 30 minutes at 378C with 5 mL of DiD per 10 6 cells. The cells were then washed twice in the same medium that is going to be used for the culture but without addition of growth solution, serum, and bFGFStato. The cells were then plated in either Xuri or aMEM cultures, as explained. The fluorescence intensity of the cells was analyzed after 1 and 4 days of culture to estimate the number of divisions effected which is proportional to the decrease of fluorescence.
Statistical analysis
The significances of differences were tested by MannWhitney U test. 
RESULTS
The amplification of viable (trypan blue negative; determined by manual counting with hemocytometer) MStroC in bulk cultures after 7 days was comparable in Xuri and combined condition to the aMEM control. Although there is no difference between these three conditions, a trend of an additive effect can be noticed when Xuri was combined with the FCS (Fig. 1) . Comparison of the confluent cell layers in Xuri medium culture and the control ones showed no differences when observed under inverted microscope without staining (Fig. 2) . Also, the proliferative history of MStroC in two conditions was not different (Fig. 3) . The analysis of CFU-F before and after culture did not reveal differences in Xuri and aMEM: CFU-F amplification fold was not different in terms of significance, although a trend of lower amplification fold can be noticed with the Xuri medium (mean expansion fold, ninefold for aMEM and Xuri 1 FTS vs. sixfold in Xuri medium [ Fig. 4A]) . However, the colony-forming efficiency (the number of colonies per a number of plated MStroC) of CFU-F is twice lower in Xuri compared to aMEM, which is significant (Fig. 4B) . Furthermore, the colonies in control medium after 7 days of culture are compact, rich in cells and of large diameter (Figs. 5A and 5B) unlike the colonies in Xuri medium, which are mainly characterized by a low cell content and small diameter (Fig. 4C ) and are only rarely of "normal" size (Fig. 5D) . These results concerning CFU-F suggest that the MStroC exhibiting at least some properties of the real MSCs (colony-forming ability) were not maintained at the same degree in Xuri and aMEM with respect neither to their concentration in MStroC nor to their individual proliferative capacity. To properly evaluate this point, we performed single-cell cultures in Xuri and control aMEM conditions. After 7 days of culture, 28.3% of MStroC proliferated and generated a colony in these single-cell cultures in aMEM, while only 8.8% if MStroC generated the clones (all clones were <10 cells per well) in Xuri medium (not shown). To test if this phenomenon is coming from a decrease in proliferative capacities of CFU-F cultures in Xuri, the entire clones from each well were plated in secondary cultures always in aMEM (one clone per well). The cells proliferated in all seeded wells when issued from aMEM primary cultures, while no proliferation was detectable for the cells issued from single-cell primary culture in Xuri medium (Fig. 6A) . Nonetheless, the CD45-MStroC cell population in both conditions presented the similar phenotypic characteristics: they were positive for CD105 CD90 and CD73 and extremely low or negative for CD34 CD14, or CD11b, CD19, and HLA-DR (Fig. 7) . The only obvious difference concerns the CD90 fluorescence intensity which was higher in Xuri-cultured cells comparing to aMEM-cultured ones. However, since in both cases cells are CD90 positive, this difference does not affect the MSC phenotype-based definition.
DISCUSSION
The results presented here show that commercial Xuri medium completed by growth solution from the same kit can support the growth and amplification of MStroC in bulk cultures to a degree similar to that of aMEM supplemented by FCS. The cells produced in these cultures express the cell surface markers considered to define "mesenchymal stem cells." 10 Functional analysis, however, reveals that in the Xuri medium cultures, the production of the cells exhibiting colony-forming ability, hence the cells closer to stem and progenitors cells (defined as functional entity) than overall MStroC population, is weaker: lower concentration in CFU-F and restriction in their individual proliferative capacity were evidenced. This negative effect of Xuri medium on the proliferative capacity, on CFU-F, is formally confirmed when MStroC were cultured directly in single-cell cultures: the capacity of colony formation in Xuri medium was three times less in CFU-F than that shown in aMEM. The individual colonies from Xuri medium were clusters of fewer than 10 cells unable to proliferate in secondary cultures (always supplied by aMEM), while in primary cultures with aMEM, the individual colonies were full sized, well cell packed, and produced rapidly confluent cell layer in secondary cultures (100% of clones). These results clearly show an insufficient supporting capacity of Xuri medium in real MSC amplification. Conversely, Xuri medium is able to support well, in the primary cultures, amplification of MStroC exhibiting post-progenitor cell characteristics. Depending on the main mechanism of therapeutic effect of MStroC, the cells obtained in Xuri medium might be either appropriate (immunomodulatory and secretory effect for example) 12 or inadequate (direct regeneration of a tissue from MSCs), 13 which remains to be further elucidated. This should be explored in more detail, since some serum-free media were shown to impact the and some others were shown to maintain the "stemness" and differentiation potential under serum-free culture conditions, but only in the presence of native extracellular matrix. 15 The limited value of immunophenotypical markers for functional potency of MStroC cell therapy products is evident, and cell therapy practitioners are continuing to search for more appropriate assays enabling the adequate releasing criteria for these products. 16 Our results show, in a quite drastic way, that the cells corresponding to the QC-oriented phenotypic definition of MSCs may contain only a minority of cells exhibiting stem cells characteristics. Even in the standard culture conditions, these cells corresponding to the "phenotypic MSC definition" contain less than one-third of colony forming cells (CFU-F) that could be candidates for MSCs; in Xuri medium, this proportion decreases to approximately 9%. At the same time, in both conditions, the cells exhibit the same complex phenotype considered to be characteristic for MSCs. Thus, this phenotypic definition is of low value if one should estimate the number of functional MSCs in cell therapy product, but can be of interest for estimation of MStroC (mainly postprogenitor populations) that might exhibit immunomodulatory and secretory activities.
